Mylan NV (MYL)

MYL (NASDAQ:Drugs) EQUITY
$41.91
neg -1.80
-4.10%
Today's Range: 41.58 - 43.50 | MYL Avg Daily Volume: 6,049,600
Last Update: 05/04/16 - 3:44 PM EDT
Volume: 4,332,294
YTD Performance: -19.18%
Open: $43.49
Previous Close: $43.69
52 Week Range: $37.59 - $74.66
Oustanding Shares: 508,342,710
Market Cap: 21,711,317,144
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 5
Moderate Buy 0 0 0 0
Hold 5 6 6 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.09 2.09 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 36.82
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
36.82 25.10 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-16.38% -40.87% 51.21%
GROWTH 12 Mo 3 Yr CAGR
Revenue 22.10 0.40 0.11
Net Income -9.20 0.30 0.10
EPS -27.00 0.20 0.05
Earnings for MYL:
EBITDA 2.40B
Revenue 9.43B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $1.17 $1.54 $4.91 $5.71
Number of Analysts 6 6 8 9
High Estimate $1.22 $1.63 $4.98 $6.16
Low Estimate $1.08 $1.46 $4.86 $5.08
Prior Year $0.91 $1.43 $4.30 $4.91
Growth Rate (Year over Year) 28.21% 7.69% 14.13% 16.35%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Doug Kass

 | May 4, 2016 | 12:40 PM EDT
-- The year-end financials that VRX filed on Friday disclosed a dangerously overleveraged balance sheet. Valeant has $30.3 billion in long-term debt, while goodwill totals $18.6 billion and 'intangibles' add up to $23.2 billion. In essence, the company paid up big time for a large amount of mergers and acquisitions -- and funded those transactions with a huge debt load. -- Valeant had $6 billion of book value at year's end, down $500 million from the prior quarter. Subtracting goodwill takes the company to $12.5 billion of negative book value. And if we 'guesstimate' that the value of VRX's intangible assets ultimately gets halved, the company's tangible net worth drops to  a neg
By

Doug Kass

 | May 2, 2016 | 10:18 AM EDT
The ultimate value of the company's businesses (calculated by cash flows and profits) could be insufficient relative to its liabilities to provide any value at all. The year-end financials that VRX filed on Friday disclosed a dangerously overleveraged balance sheet. Valeant has $30.3 billion in long-term debt, while goodwill totals $18.6 billion and "intangibles" add up to $23.2 billion. In essence, the company paid up big time for a large amount of mergers and acquisitions -- and funded those transactions with a huge debt load. Valeant had $6 billion of book value at year's end, down $500 million from the prior quarter. Subtracting goodwill takes the company to $12.5 billion of negative book value. And if we "guesstimate" that the value of VRX's intangible assets ultimately gets halved, the company's tangible net worth drops to  a negative $24 billion. Combined with Valeant's $30 billion of debt, that translates into a distressed and foundering company. VRX said its $30.5 billion of intangible assets represen
By

James Passeri

 | Apr 25, 2016 | 10:40 AM EDT

Valeant delighted shareholders Monday with news that Perrigo's Joseph Papa is getting into the driver's seat. 

By

Bret Jensen

 | Mar 29, 2016 | 11:30 AM EDT

Other companies have suffered following the debacle.

By

Bret Jensen

 | Mar 29, 2016 | 10:00 AM EDT

Other companies have suffered following the debacle.

By

Bret Jensen

 | Mar 22, 2016 | 9:00 AM EDT

I continue to add to my holdings incrementally. 

By

Bret Jensen

 | Mar 1, 2016 | 10:00 AM EST

Valuations of some small-cap concerns, such as Relypsa, are ridiculously cheap.

By

TheStreet

 | Feb 19, 2016 | 12:00 PM EST

David Einhorn is a man of many talents, including playing poker -- and watching where he stacks his chips investment-wise is a worthwhile endeavor...

By

Bret Jensen

 | Feb 12, 2016 | 10:00 AM EST

The market looks like it is expecting a significant domestic contraction in 2016, but I don't see it.

By

Bret Jensen

 | Jan 19, 2016 | 10:00 AM EST

The year has not started the way most pundits and prognosticators had envisioned.

Hard day for biotech. Seems like a lot of programmatic selling today. Trump possibly put...
I have to respectfully disagree with you on Gildead, David. In my view, GILD is a "value t...
Boeing has struggle since last week's huge gain in the 27th. BA jumped over 2.8% that...
While GILD has been minting money, engaging in a major share repurchasing program and inst...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.